Mila’s AI drives world’s largest study on psychedelics

2026-04-07 · Source: Mila · Field: Science & Research — Health & Medical Research, Life Sciences & Biology, Mathematics & Computational Sciences · Depth: Expert, quick

Summary

Mila's international team, in a study published April 7, 2026, in "Nature Medicine", utilized AI to conduct the world's largest analysis of psychedelics' effects on human brain function. This research pooled data from over 500 brain scans—ten times more than prior efforts—from dozens of labs across North America, South America, and Europe. The study found that psilocybin, LSD, mescaline, DMT, and ayahuasca all act similarly: they flatten functional hierarchies and allow isolated brain areas to communicate. This systematic mega-analysis, which unified inconsistent MRI data and applied Bayesian meta-analysis with AI, disrupts classic pharmacological methods and provides a new foundation for drug discovery efforts targeting mental health conditions.

Key takeaway

For Research Scientists developing new mental health treatments, this study highlights a common mechanism across diverse psychedelics. You should consider how flattening brain hierarchies could inform novel therapeutic targets beyond traditional receptor-binding approaches. This finding provides crucial data to inspire the next wave of psychedelic drug innovation, potentially accelerating breakthroughs for conditions like depression and schizophrenia.

Key insights

Psychedelics consistently flatten brain hierarchies, enabling communication between isolated regions.

Principles

• Large-scale data pooling enhances pharmaceutical innovation.
• AI can reveal common macroscopic effects across varied molecules.
• Brain functional hierarchies are disrupted by psychedelics.

Method

Inconsistent MRI data was unified, pooled at Mila, then analyzed using Bayesian meta-analysis with AI to create a probabilistic map of brain changes.

In practice

• Inform drug discovery for mental health conditions.
• Challenge classic pharmacological receptor-binding focus.

Topics

• Psychedelics Research
• AI in Neuroscience
• Brain Function
• Drug Discovery
• Mental Health
• Bayesian Meta-analysis

Best for: Research Scientist, AI Scientist, Data Scientist

Related on AIssential

• How we’re using AI tools to improve psychedelic-drug research — AI-powered simulation tools can standardize and scale specialized therapy training using real-world interaction data.
• AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials — AlphaFold, known for protein understanding, is now being tested for drug design capabilities.
• AI and the Dopamine Dilemma: Is Technology Rewiring Your Brain’s Happiness? — AI's instant gratification and hyper-personalization may reduce dopamine sensitivity and increase depressive symptoms.
• Accelerating discovery of liver disease mechanisms — AI-driven literature analysis can uncover novel biological hypotheses and candidate therapies for complex diseases.
• DeepER-Med: Advancing Deep Evidence-Based Research in Medicine Through Agentic AI — DeepER-Med enhances medical AI trustworthiness via explicit evidence appraisal and agentic collaboration.
• AI Now Reads Your Mind — AI is transforming workplace productivity, cloud infrastructure, and human-computer interaction, including direct brain input.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Mila.